U.S. Capital Wealth Advisors LLC Invests $206,000 in Walgreens Boots Alliance, Inc. (NASDAQ:WBA)

U.S. Capital Wealth Advisors LLC acquired a new stake in shares of Walgreens Boots Alliance, Inc. (NASDAQ:WBA) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 7,902 shares of the pharmacy operator’s stock, valued at approximately $206,000.

A number of other institutional investors have also recently made changes to their positions in the business. EverSource Wealth Advisors LLC raised its holdings in shares of Walgreens Boots Alliance by 308.4% in the third quarter. EverSource Wealth Advisors LLC now owns 1,119 shares of the pharmacy operator’s stock worth $25,000 after buying an additional 845 shares during the last quarter. Highlander Capital Management LLC purchased a new position in Walgreens Boots Alliance in the 4th quarter worth $26,000. Venturi Wealth Management LLC lifted its position in Walgreens Boots Alliance by 1,241.8% during the 4th quarter. Venturi Wealth Management LLC now owns 1,060 shares of the pharmacy operator’s stock worth $28,000 after acquiring an additional 981 shares during the period. Rocky Mountain Advisers LLC acquired a new stake in Walgreens Boots Alliance during the 4th quarter worth about $30,000. Finally, Tyler Stone Wealth Management grew its stake in Walgreens Boots Alliance by 1,280.0% during the 3rd quarter. Tyler Stone Wealth Management now owns 1,380 shares of the pharmacy operator’s stock valued at $31,000 after purchasing an additional 1,280 shares during the last quarter. Institutional investors and hedge funds own 58.59% of the company’s stock.

Insider Buying and Selling

In related news, Director Inderpal S. Bhandari purchased 3,000 shares of the company’s stock in a transaction dated Thursday, April 11th. The stock was acquired at an average cost of $18.05 per share, for a total transaction of $54,150.00. Following the completion of the transaction, the director now directly owns 3,000 shares of the company’s stock, valued at $54,150. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other Walgreens Boots Alliance news, CFO Manmohan Mahajan bought 6,000 shares of Walgreens Boots Alliance stock in a transaction on Tuesday, April 2nd. The shares were bought at an average price of $19.38 per share, for a total transaction of $116,280.00. Following the completion of the transaction, the chief financial officer now directly owns 166,969 shares of the company’s stock, valued at $3,235,859.22. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Inderpal S. Bhandari purchased 3,000 shares of the stock in a transaction dated Thursday, April 11th. The shares were acquired at an average price of $18.05 per share, with a total value of $54,150.00. Following the completion of the acquisition, the director now owns 3,000 shares in the company, valued at approximately $54,150. The disclosure for this purchase can be found here. 17.40% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. HSBC reiterated a “reduce” rating and issued a $20.00 price target (down previously from $27.00) on shares of Walgreens Boots Alliance in a report on Tuesday, February 20th. TD Cowen lowered their price target on shares of Walgreens Boots Alliance from $37.00 to $35.00 and set a “buy” rating on the stock in a report on Wednesday, April 3rd. Leerink Partnrs reiterated a “market perform” rating on shares of Walgreens Boots Alliance in a research note on Monday, February 26th. UBS Group lowered their target price on Walgreens Boots Alliance from $25.00 to $22.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 3rd. Finally, SVB Leerink reduced their price target on Walgreens Boots Alliance from $23.00 to $22.00 and set a “market perform” rating for the company in a research report on Monday, March 18th. Four equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $24.36.

Walgreens Boots Alliance Stock Performance

NASDAQ:WBA opened at $17.23 on Thursday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.32 and a current ratio of 0.66. The stock has a market capitalization of $14.86 billion, a PE ratio of -2.46, a P/E/G ratio of 1.10 and a beta of 0.80. Walgreens Boots Alliance, Inc. has a fifty-two week low of $17.21 and a fifty-two week high of $32.89. The company has a fifty day moving average of $19.43 and a two-hundred day moving average of $21.53.

Walgreens Boots Alliance (NASDAQ:WBA) last issued its quarterly earnings results on Thursday, March 28th. The pharmacy operator reported $1.20 earnings per share for the quarter, beating analysts’ consensus estimates of $0.82 by $0.38. The firm had revenue of $37.05 billion for the quarter, compared to analyst estimates of $35.86 billion. Walgreens Boots Alliance had a negative net margin of 4.18% and a positive return on equity of 12.11%. Walgreens Boots Alliance’s quarterly revenue was up 6.3% compared to the same quarter last year. During the same period last year, the company posted $1.16 EPS. As a group, research analysts forecast that Walgreens Boots Alliance, Inc. will post 3.23 earnings per share for the current fiscal year.

Walgreens Boots Alliance Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, June 12th. Stockholders of record on Tuesday, May 21st will be paid a $0.25 dividend. This represents a $1.00 annualized dividend and a dividend yield of 5.80%. The ex-dividend date of this dividend is Monday, May 20th. Walgreens Boots Alliance’s dividend payout ratio is currently -14.29%.

Walgreens Boots Alliance Profile

Walgreens Boots Alliance, Inc operates as a healthcare, pharmacy, and retail company in the United States, the United Kingdom, Germany, and internationally. It operates through three segments: U.S. Retail Pharmacy, International, and U.S. Healthcare. The U.S. Retail Pharmacy segment engages in operation of the retail drugstores, health and wellness services, specialty, and home delivery pharmacy services, which offers health and wellness, beauty, personal care and consumables, and general merchandise.